<DOC>
	<DOCNO>NCT00711620</DOCNO>
	<brief_summary>The purpose study evaluate efficacy thymosin alpha 1 treat severe sepsis .</brief_summary>
	<brief_title>Efficacy Thymosin alpha1 Severe Sepsis</brief_title>
	<detailed_description>Severe sepsis disease infectious origin high risk death . Over past decade , thymosin alpha1 already provide clinician additional weapon fight infectious disease , unknown whether thymosin alpha1 effective treat severe sepsis .</detailed_description>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Thymalfasin</mesh_term>
	<criteria>Severe sepsis accord ACCP/CCM criterion Patient legally authorize representative able provide inform consent Subject le 18 year 85 year age If female , subject pregnant nursing Subject receive immunosuppressive therapy cyclosporine , azothioprine , cancerrelated chemotherapy Patient expect survive 28 day uncorrectable medical condition , poorly control neoplasm endstage disease History bone marrow , lung , liver , pancreas , smallbowel transplantation Acute pancreatitis establish source infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>sepsis</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Thymosin</keyword>
</DOC>